Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Website: graphitebio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 64.8%. Free cash flow yield -19.6% (LTM)

Entry Point: Share price is 71.9% higher than minimum and 89.7% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: GRPH
Share price, USD:  (0.0%)3.18
year average price 2.71  


year start price 3.22 2023-05-08

min close price 2.18 2023-09-11

max close price 3.73 2024-03-11

current price 3.18 2024-05-07
Common stocks: 406 058 772

Dividend Yield:  64.8%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 1 291
Net Debt ($m): -175
EV (Enterprise Value): 1 116
Price to Book: 7.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-11-16Zacks Investment Research

What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GRPH GRPH GRPH GRPH GRPH GRPH
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-13 2023-08-14 2023-05-11 2023-03-20 2022-11-09
acceptedDate 2024-02-27 16:11:05 2023-11-13 16:10:39 2023-08-14 17:04:38 2023-05-11 16:11:53 2023-03-20 16:11:26 2022-11-09 16:14:49
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 10M 0 0 0 0 0
costOfRevenue 142 000 800 000 2M 0 0 0
grossProfit 10M -800 000 -2M 0 0 0
grossProfitRatio 0.986 0 0 0 0 0
researchAndDevelopmentExpenses 1000.000 2M 14M 16M 18M 18M
generalAndAdministrativeExpenses 15M 11M 7M 8M 8M 8M
sellingAndMarketingExpenses -142 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 14M 11M 7M 8M 8M 8M
otherExpenses 75 000 11M 37M 3M 0 0
operatingExpenses 14M 25M 21M 24M 27M 26M
costAndExpenses 15M 25M 21M 24M 27M 26M
interestIncome 3M 3M 3M 3M 2M 1M
interestExpense -5M 0 0 5M 2M 1M
depreciationAndAmortization 142 000 762 000 849 000 6M 682 000 652 000
ebitda -14M -25M 17M -21M -27M -26M
ebitdaratio -1.413 0 0 0 0 0
operatingIncome -15M -25M -58M -26M -27M -26M
operatingIncomeRatio -1.427 0 0 0 0 0
totalOtherIncomeExpensesNet -8M 3M -37M 3M 2M 1M
incomeBeforeTax -23M -22M -55M -24M -25M -25M
incomeBeforeTaxRatio -2.239 0 0 0 0 0
incomeTaxExpense -31M -762 000 34M -3M -2M -1M
netIncome -23M -22M -55M -21M -22M -23M
netIncomeRatio -2.239 0 0 0 0 0
eps -0.400 -0.390 -0.970 -0.380 -0.400 -0.420
epsdiluted -0.400 -0.390 -0.970 -0.380 -0.400 -0.420
weightedAverageShsOut 58M 57M 57M 56M 56M 55M
weightedAverageShsOutDil 58M 57M 57M 56M 56M 55M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GRPH GRPH GRPH GRPH GRPH GRPH
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-13 2023-08-14 2023-05-11 2023-03-20 2022-11-09
acceptedDate 2024-02-27 16:11:05 2023-11-13 16:10:39 2023-08-14 17:04:38 2023-05-11 16:11:53 2023-03-20 16:11:26 2022-11-09 16:14:49
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 186M 183M 129M 70M 48M 56M
shortTermInvestments 0 51M 118M 194M 220M 235M
cashAndShortTermInvestments 186M 234M 247M 264M 268M 292M
netReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
otherCurrentAssets 2M 5M 5M 6M 7M 7M
totalCurrentAssets 188M 239M 251M 270M 275M 298M
propertyPlantEquipmentNet 321 000 26M 34M 37M 28M 20M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 114 000 2M 2M 0 15M 13M
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 0 0 355 000 3M 3M 3M
totalNonCurrentAssets 435 000 27M 36M 40M 47M 36M
otherAssets 0 0 0 0 0 0
totalAssets 188M 266M 287M 310M 322M 335M
accountPayables 250 000 4M 3M 2M 3M 4M
shortTermDebt 285 000 3M 3M 3M 4M 5M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 5M 7M 0 0 0
otherCurrentLiabilities 4M 34 000 55 000 9M 6M 5M
totalCurrentLiabilities 5M 13M 12M 14M 13M 14M
longTermDebt 77 000 50M 51M 1M 2M 2M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities -1.000 0 0 18M 11M -4M
totalNonCurrentLiabilities 76 999 50M 51M 19M 13M 5M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 77 000 53M 54M 5M 6M 7M
totalLiabilities 5M 62M 63M 34M 26M 18M
preferredStock 0 0 0 0 0 0
commonStock 1000.000 1000.000 1000.000 1000.000 1000.000 1000.000
retainedEarnings -367M -344M -322M -266M -242M -218M
accumulatedOtherComprehensiveIncomeLoss 0 -95 000 -271 000 -469 000 -1M -2M
othertotalStockholdersEquity 551M 548M 546M 543M 540M 536M
totalStockholdersEquity 184M 204M 224M 276M 296M 316M
totalEquity 184M 204M 224M 276M 296M 316M
totalLiabilitiesAndStockholdersEquity 188M 266M 287M 310M 322M 335M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 188M 266M 287M 310M 322M 335M
totalInvestments 114 000 51M 118M 194M 236M 249M
totalDebt 362 000 53M 54M 5M 6M 7M
netDebt -185M -130M -75M -65M -42M -49M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GRPH GRPH GRPH GRPH GRPH GRPH
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-13 2023-08-14 2023-05-11 2023-03-20 2022-11-09
acceptedDate 2024-02-27 16:11:05 2023-11-13 16:10:39 2023-08-14 17:04:38 2023-05-11 16:11:53 2023-03-20 16:11:26 2022-11-09 16:14:49
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -23M -22M -55M -24M -25M -25M
depreciationAndAmortization 142 000 762 000 849 000 654 000 682 000 652 000
deferredIncomeTax -41M 6M 35M 0 0 0
stockBasedCompensation 2M 2M 3M 3M 4M 3M
changeInWorkingCapital -43M 3M 1M -1M -3M -2M
accountsReceivables 0 0 0 0 -14 000 0
inventory 0 0 0 0 0 0
accountsPayables -4M 2M -498 000 -591 000 -1M 392 000
otherWorkingCapital -39M 623 000 2M -470 000 -1M -3M
otherNonCashItems 59M 1M 1M 4000.000 419 000 954 000
netCashProvidedByOperatingActivities -46M -9M -14M -21M -22M -22M
investmentsInPropertyPlantAndEquipment -50 000 -5M -6M -383 000 -1M -915 000
acquisitionsNet 679 000 888 000 337 000 0 0 0
purchasesOfInvestments 1000.000 -888 000 -1000.000 -28M -66M -86M
salesMaturitiesOfInvestments 46M 68M 78M 72M 80M 90M
otherInvestingActivites 0 888 000 0 0 0 0
netCashUsedForInvestingActivites 47M 64M 72M 43M 14M 3M
debtRepayment 0 0 0 0 0 0
commonStockIssued 66 000 16 000 175 000 0 20 000 0
commonStockRepurchased 67 000 -8000.000 -51 000 -8000.000 64 000 -64 000
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -67 000 0 0 0 160 000 5000.000
netCashUsedProvidedByFinancingActivities 66 000 8000.000 124 000 -8000.000 244 000 -59 000
effectOfForexChangesOnCash 108M -52M -56M 0 0 0
netChangeInCash 3M 54M 59M 22M -9M -19M
cashAtEndOfPeriod 186M 185M 130M 72M 49M 58M
cashAtBeginningOfPeriod 183M 130M 72M 49M 58M 77M
operatingCashFlow -46M -9M -14M -21M -22M -22M
capitalExpenditure -50 000 -5M -6M -383 000 -1M -915 000
freeCashFlow -46M -14M -19M -21M -23M -23M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-08 22:00 ET
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
2023-11-15 12:00 ET
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
2023-06-23 11:00 ET
Graphite Bio Announces Departure of Chief Financial Officer
2023-03-20 20:05 ET
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
2023-02-22 21:05 ET
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
2023-01-05 21:05 ET
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
2022-12-11 15:00 ET
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
2022-11-21 13:00 ET
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
2022-11-09 21:05 ET
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
2022-11-03 13:05 ET
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
2022-10-11 12:00 ET
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
2022-09-06 12:00 ET
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-11 20:05 ET
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
2022-08-11 12:16 ET
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
2022-06-01 12:00 ET
Graphite Bio Announces Participation in Jefferies Healthcare Conference
2022-05-16 10:00 ET
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
2022-05-12 20:05 ET
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
2022-05-04 12:00 ET
Graphite Bio Announces Participation in Upcoming Investor Conferences
2022-05-03 12:00 ET
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
2022-05-02 20:38 ET
Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program
2022-03-28 12:00 ET
Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
2022-03-23 12:00 ET
Graphite Bio Announces Formation of Scientific Advisory Board
2022-03-21 12:25 ET
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
2022-03-03 13:00 ET
Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference
2022-03-02 13:00 ET
Graphite Bio Appoints Alethia Young as Chief Financial Officer
2022-01-27 13:00 ET
Graphite Bio Announces Participation in Upcoming Investor Conferences
2021-12-11 14:00 ET
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition
2021-12-07 13:00 ET
Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease
2021-11-17 13:00 ET
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease
2021-11-10 21:05 ET
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results
2021-11-04 13:13 ET
Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition
2021-10-21 12:00 ET
Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit
2021-10-12 17:00 ET
Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention
2021-10-05 12:00 ET
Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention
2021-08-30 12:00 ET
Graphite Bio Announces Participation in Upcoming September Investor Conferences
2021-08-12 20:05 ET
Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results
2021-06-30 21:15 ET
Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-06-25 01:08 ET
Graphite Bio Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-02-27 16:11 ET
Graphite Bio, Inc. reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Graphite Bio, Inc. reported for 2023 q4
SEC form 10
2023-11-13 16:10 ET
Graphite Bio, Inc. reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Graphite Bio, Inc. reported for 2023 q3
SEC form 6
2023-08-23 16:06 ET
Graphite Bio, Inc. published news for 2023 q2
SEC form 10
2023-08-14 17:04 ET
Graphite Bio, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Graphite Bio, Inc. reported for 2023 q2
SEC form 6
2023-08-02 16:07 ET
Graphite Bio, Inc. published news for 2023 q2
SEC form 6
2023-08-01 20:06 ET
Graphite Bio, Inc. published news for 2023 q2
SEC form 6
2023-07-20 08:02 ET
Graphite Bio, Inc. published news for 2023 q2
SEC form 6
2023-06-23 07:05 ET
Graphite Bio, Inc. published news for 2023 q1
SEC form 6
2023-06-06 16:05 ET
Graphite Bio, Inc. published news for 2023 q1
SEC form 10
2023-05-11 16:11 ET
Graphite Bio, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Graphite Bio, Inc. reported for 2023 q1
SEC form 6
2023-04-27 16:06 ET
Graphite Bio, Inc. published news for 2023 q1
SEC form 10
2023-03-20 16:11 ET
Graphite Bio, Inc. reported for 2022 q4
SEC form 6
2023-03-20 16:06 ET
Graphite Bio, Inc. reported for 2022 q4
SEC form 10
2023-03-20 00:00 ET
Graphite Bio, Inc. reported for 2022 q4
SEC form 8
2023-03-20 00:00 ET
Graphite Bio, Inc. reported for 2022 q4
SEC form 6
2023-03-16 16:05 ET
Graphite Bio, Inc. published news for 2022 q4
SEC form 6
2023-02-22 16:58 ET
Graphite Bio, Inc. published news for 2022 q4
SEC form 6
2023-01-05 16:06 ET
Graphite Bio, Inc. published news for 2022 q4
SEC form 6
2022-12-12 06:10 ET
Graphite Bio, Inc. published news for 2022 q3
SEC form 10
2022-11-09 16:14 ET
Graphite Bio, Inc. reported for 2022 q3
SEC form 6
2022-11-09 16:07 ET
Graphite Bio, Inc. reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Graphite Bio, Inc. reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Graphite Bio, Inc. reported for 2022 q3
SEC form 6
2022-11-03 09:05 ET
Graphite Bio, Inc. published news for 2022 q3
SEC form 10
2022-08-11 16:11 ET
Graphite Bio, Inc. reported for 2022 q2
SEC form 6
2022-08-11 16:07 ET
Graphite Bio, Inc. reported for 2022 q2
SEC form 6
2022-08-11 08:00 ET
Graphite Bio, Inc. published news for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Graphite Bio, Inc. reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Graphite Bio, Inc. reported for 2022 q2
SEC form 6
2022-07-13 16:31 ET
Graphite Bio, Inc. published news for 2022 q2
SEC form 6
2022-06-23 16:26 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:40 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:39 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:38 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:38 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:37 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:36 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:35 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:35 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-06-22 17:34 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-16 06:03 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 10
2022-05-12 16:12 ET
Graphite Bio, Inc. reported for 2022 q1
SEC form 6
2022-05-12 16:06 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Graphite Bio, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Graphite Bio, Inc. reported for 2022 q1
SEC form 6
2022-04-29 16:03 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 6
2022-04-05 17:57 ET
Graphite Bio, Inc. published news for 2022 q1
SEC form 10
2022-03-21 08:31 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 6
2022-03-21 08:25 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 10
2022-03-21 00:00 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 8
2022-03-21 00:00 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 6
2022-03-02 16:06 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 6
2022-02-18 19:02 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 6
2022-02-18 18:56 ET
Graphite Bio, Inc. published news for 2021 q4
SEC form 6
2021-12-20 16:08 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 6
2021-12-08 06:02 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-17 09:23 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-16 16:00 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 10
2021-11-10 16:10 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-10 16:05 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Graphite Bio, Inc. published news for 2021 q3
SEC form 10
2021-08-12 16:13 ET
Graphite Bio, Inc. published news for 2021 q2
SEC form 6
2021-08-12 16:06 ET
Graphite Bio, Inc. published news for 2021 q2
SEC form 8
2021-08-12 00:00 ET
Graphite Bio, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Graphite Bio, Inc. published news for 2021 q2
SEC form 6
2021-06-30 17:15 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:20 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:20 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:19 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:19 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:19 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:16 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:14 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:14 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:14 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:13 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:12 ET
Graphite Bio, Inc. published news for 2021 q1
SEC form 6
2021-06-24 21:12 ET
Graphite Bio, Inc. published news for 2021 q1